



Somerset builds a more resilient ophthalmics portfolio with the launch of 4 new products

Somerset Pharma is pleased to announce the launch of four new USFDA approved sterile ophthalmic products as part of its growing ophthalmics portfolio.

- Bepotastine Besilate 1.5% (generic BEPREVE®) is an antihistamine eye drop used to treat itching caused by allergic conjunctivitis.
- Proparacaine Hydrochloride 0.5% (generic ALCAINE®) is a topical local anesthetic for short duration corneal and conjunctival procedures.
- Travoprost 0.004% (generic TRAVATAN Z[®]) is a prostaglandin analog used to relieve ocular hypertension and treat glaucoma.
- Moxifloxacin 0.5% (generic VIGAMOX®) an antibiotic indicated for the treatment of bacterial conjunctivitis. The addition of these four products to Somerset's growing portfolio of ophthalmic products further strengthens our commitment to providing high quality medication at affordable prices.



"We are grateful for the opportunity to supply quality products to our healthcare partners and contribute to their mission of providing exceptional patient care. We also aim to make the supply chain for these products more resilient, making them easily accessible to our healthcare partners and the patients under their care."

- Arun Menon,

Chief Commercial Officer, Somerset Pharma

We take this opportunity to thank our healthcare partners for your constant support and faith in the company. We look forward to achieving and celebrating many new milestones together.

Best wishes,

Somerset Team

This product is available for direct purchase and will also be available to your wholesaler shortly. Speak to your Somerset representative or email sales@somersetpharma.com for more information.